Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.

Manoj Kumar SharmaSuman L NayakEkta GuptaAshish KatariaShiv Kumar Sarin

Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)

Full-dose sofosbuvir-based DAA therapy using generics is highly effective for individuals with HCV infection and CKD including advanced CKD (CKD stage 4 or 5 with an e-GFR <30 mL/min or those on dialysis).

Keyphrases

hepatitis c virus
chronic kidney disease
end stage renal disease
human immunodeficiency virus
stem cells
hiv infected
smoking cessation